Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Alliance for Clinical Trials in Oncology

Status: Active, not recruiting

Conditions: Acute Leukemia; Multiple Myeloma; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome

Treatments: Genetic: cytogenetic analysis

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00048958

CALGB-8461

CDR0000256897 (Registry Identifier)

3U24CA114725-09S1 (U.S. NIH Grant/Contract)

NCI-2009-00494 (Registry Identifier)

Details and patient eligibility

About

Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.

Enrollment: 9,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

1. Patients from adjuncts are eligible if the Main Member Cytogenetics laboratory has agreed to process samples from that adjunct.
2. Within one month of registration on CALGB 8461, register onto a CALGB treatment study for previously untreated AML, ALL, MDS, or MM patients.
3. Simultaneously with registration on CALGB 8461, register patients within the continental United States onto CALGB 9665 (LTB).

Trial design

9,000 participants in 1 patient group

No treatment

Description:

Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.

Treatment:

Genetic: cytogenetic analysis